DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Rating of “Hold” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been given an average recommendation of “Hold” by the six brokerages that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company.

A number of brokerages have commented on DSRLF. Zacks Research raised DiaSorin to a “hold” rating in a report on Tuesday, May 12th. UBS Group cut shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Finally, BNP Paribas Exane upgraded DiaSorin to a “neutral” rating in a research note on Wednesday, January 28th.

DiaSorin Stock Performance

Shares of OTCMKTS DSRLF opened at $67.00 on Thursday. The business’s 50 day moving average is $70.15 and its 200-day moving average is $74.96. DiaSorin has a 1-year low of $66.50 and a 1-year high of $112.30.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.